Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLCSeung Yeon Oh, Mi Ran Yun|Clinical Cancer Research|2022Cited by 47
The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLCSeung Yeon Oh, Mi Ran Yun|Cell Reports Medicine|2025Cited by 5